Most Read Articles
6 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
4 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Low-dose bevacizumab effective for treating retinopathy of prematurity

09 Jul 2018

Low-dose bevacizumab yields excellent retinal structural outcomes in the treatment of retinopathy of prematurity (ROP), although a number of infants may still require additional treatment, as shown in a study.

A total of 61 premature infants with type 1 ROP received bevacizumab intravitreal injections at de-escalating doses of 0.25, 0.125, 0.063 or 0.031 mg in the study eye. If needed, fellow eyes received treatment at one-dose level higher: 0.625, 0.25, 0.125 or 0.063 mg, respectively. Additional treatment was or was not given after 4 weeks.

The main outcomes investigated were early and late ROP recurrences, additional treatments, and structural outcomes after 6 months.

Additional treatment was administered to 25 of 61 study eyes (41 percent) due to early treatment failure (within 4 weeks; n=3), late recurrence of ROP (after 4 weeks; n=11) or persistent avascular retina (n=11).

Specifically, retreatment for early failure or late recurrence occurred in two of 11 eyes (18 percent) given 0.25 mg, four of 16 eyes (25 percent) given 0.125 mg, eight of 24 eyes (33 percent) given 0.063 mg and none of 10 eyes (0 percent) given 0.031 mg.

By 6 months corrected age, 56 infants had ROP regression with normal posterior poles, one developed a stage 5 retinal detachment, and four had died of pre-existing medical conditions.

Further investigations are being conducted to test lower doses of bevacizumab, which may lead to enhanced normal retinal vascularization while posing lower systemic risk, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Living a sedentary lifestyle may increase the risk of cardiovascular diseases (CVD) even in people with healthy body mass index (BMI), reports a new study.
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
4 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.